Markets:

Overview

News

Currencies

International

Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

60.23 -2.62 (-4.18%)

Streaming Delayed Price Updated: 12:27 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack

March 05, 2026

Via StockStory

3 Reasons HAE is Risky and 1 Stock to Buy Instead

March 03, 2026

Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65.64 per share. This was partly d...

Via StockStory

Topics Stocks Supply Chain

3 Profitable Stocks with Open Questions

March 01, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call

February 12, 2026

Haemonetics’ fourth quarter results were met with a negative market reaction, reflecting investor caution despite the company’s performance exceeding Wall Street’s revenue and earnings expectations....

Via StockStory

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results

February 06, 2026

Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%...

Via StockStory

Haemonetics HAE Q3 2026 Earnings Call Transcript ↗

February 05, 2026

Haemonetics HAE Q3 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Haemonetics’s (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars

February 05, 2026

Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%...

Via StockStory

What To Expect From Haemonetics’s (HAE) Q4 Earnings

February 03, 2026

Blood products company Haemonetics (NYSE:HAE). will be reporting earnings this Thursday before market open. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: Haemonetics (NYSE:HAE)

January 28, 2026

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - specialty stocks, including Haemonetics (NYSE:HAE) and its peers.

Via StockStory

The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market

January 23, 2026

As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

1 Russell 2000 Stock to Keep an Eye On and 2 Facing Headwinds

January 22, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

3 Value Stocks with Open Questions

January 20, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

1 Cash-Producing Stock Worth Your Attention and 2 Facing Challenges

January 14, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

January 12, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

1 Small-Cap Stock Worth Your Attention and 2 We Avoid

January 08, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

3 Low-Volatility Stocks We Think Twice About

January 01, 2026

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Why Haemonetics (HAE) Shares Are Trading Lower Today

December 15, 2025

Shares of blood products company Haemonetics (NYSE:HAE). fell 4.3% in the afternoon session after Needham downgraded the stock from 'Buy' to 'Hold', citing concerns about growing competition.

Via StockStory

Topics Artificial Intelligence

Why Haemonetics (HAE) Stock Is Down Today

December 11, 2025

Shares of blood products company Haemonetics (NYSE:HAE). fell 2.1% in the morning session after Citigroup downgraded the stock to "Neutral" from "Buy."

Via StockStory

Topics Economy

Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy

3 Reasons to Sell HAE and 1 Stock to Buy Instead

November 17, 2025

Although Haemonetics (currently trading at $74.04 per share) has gained 6.7% over the last six months, it has trailed the S&P 500’s 13% return during that period. This may have investors wondering how...

Via StockStory

Topics Stocks Supply Chain

1 Mooning Stock with Impressive Fundamentals and 2 We Ignore

November 13, 2025

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage...

Via StockStory

Topics Artificial Intelligence

5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call

November 13, 2025

Haemonetics’ third quarter results were met with a significant positive market reaction, reflecting both a beat on Wall Street’s revenue and profit expectations and effective execution across its core...

Via StockStory

Topics Earnings

SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million ↗

November 08, 2025

SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million

Via The Motley Fool

Topics Regulatory Compliance

Why Haemonetics Stock Was on Fire Thursday ↗

November 07, 2025

The hematology specialist delivered a satisfying beat-and-raise fiscal second quarter.

Via The Motley Fool

HAE Q3 Deep Dive: Margin Expansion and Portfolio Rationalization Drive Outperformance

November 07, 2025

Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per share was...

Via StockStory

Why Are Haemonetics (HAE) Shares Soaring Today

November 06, 2025

Shares of blood products company Haemonetics (NYSE:HAE). jumped 22.1% in the morning session after the company reported third-quarter results that surpassed analyst expectations and raised its...

Via StockStory

Topics Artificial Intelligence Economy Government

Datadog, Fastly, Planet Fitness, Air Products And Other Big Stocks Moving Higher On Thursday ↗

November 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%

November 06, 2025

Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.